Royalty Pharma plc (RPRX) concluded trading on Thursday at a closing price of $24.28, with 4.36 million shares of worth about $105.76 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -9.77% during that period and on December 19, 2024 the price saw a loss of about -0.78%. Currently the company’s common shares owned by public are about 446.04M shares, out of which, 380.55M shares are available for trading.
Stock saw a price change of -3.69% in past 5 days and over the past one month there was a price change of -6.65%. Year-to-date (YTD), RPRX shares are showing a performance of -13.56% which decreased to -12.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $24.46 but also hit the highest price of $31.66 during that period. The average intraday trading volume for Royalty Pharma plc shares is 2.60 million. The stock is currently trading -5.84% below its 20-day simple moving average (SMA20), while that difference is down -8.39% for SMA50 and it goes to -12.07% lower than SMA200.
Royalty Pharma plc (NASDAQ: RPRX) currently have 446.04M outstanding shares and institutions hold larger chunk of about 70.64% of that.
The stock has a current market capitalization of $14.31B and its 3Y-monthly beta is at 0.47. PE ratio of stock for trailing 12 months is 9.50, while it has posted earnings per share of $2.56 in the same period. It has Quick Ratio of 1.54 while making debt-to-equity ratio of 1.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RPRX, volatility over the week remained 2.22% while standing at 1.83% over the month.
Stock’s fiscal year EPS is expected to drop by -11.36% while it is estimated to increase by 10.36% in next year. EPS is likely to shrink at an annualized rate of -1.30% for next 5-years, compared to annual growth of 2.23% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on June 03, 2024 offering a Neutral rating for the stock and assigned a target price of $28 to it. Coverage by UBS stated Royalty Pharma plc (RPRX) stock as a Buy in their note to investors on June 14, 2022, suggesting a price target of $47 for the stock. On May 13, 2022, Scotiabank Initiated their recommendations, while on April 27, 2022, Goldman Initiated their ratings for the stock with a price target of $56. Stock get an Overweight rating from JP Morgan on April 14, 2022.
